Use of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer: A Real-Life Experience in Morocco
Journal of Cancer Therapy · 2026 · 17 (04) · 205-214
DOI: 10.4236/jct.2026.174020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Therapy, 2026. Verfasst von Diango Keita und 13 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Keita, D., Nejjari, S., Oufrid, A., Hakym, S. E., Hilali, H. E., Chbihi, C., Aabboub, B., Belcadi, M., Alem, M., Amaadour, L., Oualla, K., Benbrahim, Z., Arifi, S., & Mellas, N. (2026). Use of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer: A Real-Life Experience in Morocco. Journal of Cancer Therapy, 17(04), 205-214. https://doi.org/10.4236/jct.2026.174020
Vancouver
Keita D, Nejjari S, Oufrid A, Hakym SE, Hilali HE, Chbihi C, et al. Use of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer: A Real-Life Experience in Morocco. Journal of Cancer Therapy. 2026;17(04):205-214. doi:10.4236/jct.2026.174020
BibTeX
@article{Keita2026,
author = {Keita, Diango and Nejjari, Sara and Oufrid, Abir and Hakym, Samia El and Hilali, Hafssa El and Chbihi, Chaymae and Aabboub, Basma and Belcadi, Mounir and Alem, Mehdi and Amaadour, Lamiae and Oualla, Karima and Benbrahim, Zineb and Arifi, Samia and Mellas, Nawfel},
title = {Use of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer: A Real-Life Experience in Morocco},
journal = {Journal of Cancer Therapy},
year = {2026},
volume = {17},
number = {04},
pages = {205--214},
doi = {10.4236/jct.2026.174020}
}
EUVIMED